Clinical Significance Of Serum SFas And SFasL In Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Objective:Through detecting the serum sFas and sFasL level of the patient with the breast cancer before and after the neoadjuvant chemotherapy, compare the change trend, carry out preliminary discussion on sFas source and clinical guidance significance, and try to provide more convenient and objective clinical basis for formulating the clinical diagnosis and treatment scheme of the breast cancer..Patients and Methods:1, Screen17women patients with invasive ductal carcinoma at the age from30to65, and they conformed to the indication of the neoadjuvant chemotherapy. The control group was composed of15healthy women without high blood pressure, diabetes and other chronic diseases, and meanwhile, the patients with blood disease history or other malignancies were excluded.2, Adopt the enzyme linked immunosorbent assay (ELISA) to test the sFas and sFasL content in the serum of the patients with the breast cancer and the healthy women.3, Adopt GraphPad.Prism.v5.0for windows statistical software to carry out the analysis.Results:1, The content of sFas in the serum of the patients with the breast cancer before the neoadjuvant chemotherapy was low (39.58±17.38). Compared with the normal group (20.56±6.807), it turns out that there is no obvious statistical significance (p=0.2122). After the neoadjuvant chemotherapy, the concentration in the serum of the patients increased (302.8±72.86). Compared with pre-neoadjuvant chemotherapy and normal control group on the concentration, there is obvious statistical difference (p<0.05). Besides, compared with the pre-neoadjuvant chemotherapy, the concentration of the serum in the post-operative patients after the neoadjuvant chemotherapy (i.e. pre-operation) does not have obvious statistical difference (p=0.4259).2, As for the patients with estrogen receptor positive breast cancer, sFas serum content (before:20.60±9.974; after:175.4±59.15) of the effective neoadjuvant chemotherapy group (CR+PR) was obviously increased compared with that of the ineffective patients (SD+PD)(before:19.82±9.143and511.6±381.6), which contributes to obvious difference (P<0.05).3, Before and after the neoadjuvant chemotherapy, or after the operation, or compared with the control group, sFasL does not have any statistical significance (p=0.1160, p=2530, p=0.5845)..Conclusion:(1) sFas in the patient’s serum is remarkably increased after the neoadjuvant chemotherapy.(2) As for the patients with ER positive breast cancer, it is feasible to observe their serum concentration change through observation and early predict the curative effect of the neoadjuvant chemotherapy.(3) sFasL does not have obvious change in the patients’serum before and after the treatment.